Royal jelly attenuates azathioprine induced toxicity in rats.
In the present study, we investigated the potential protective effects of royal jelly against azathioprine-induced toxicity in rat. Intraperitoneal administration of azathioprine (50 mg/kgB.W.) induced a significant decrease in RBCs count, Hb concentration, PCV%, WBCs count, differential count and platelet count, hepatic antioxidant enzymes (reduced glutathione and glutathione s-transferase) and increase of serum transaminases (alanine aminotransferase and aspartate aminotransferase enzymes) activities, alkaline phosphatase and malondialdehyde formation. Azathioprine induced hepatotoxicity was reflected by marked pathological changes in the liver. Oral administration of royal jelly (200 mg/kgB.W.) was efficient in counteracting azathioprine toxicity whereas it altered the anemic condition, leucopenia and thrombocytopenia induced by azathioprine. Furthermore, royal jelly exerted significant protection against liver damage induced by azathioprine through reduction of the elevated activities of serum hepatic enzymes. Moreover, royal jelly blocked azathioprine-induced lipid peroxidation through decreasing the malondialdehyde formation. In conclusion, royal jelly possesses a capability to attenuate azathioprine-induced toxicity.
Department of Clinical Pathology, Faculty of Veterinary Medicine, Beni-Suef University, Egypt. Electronic address: Walaa_msa@yahoo.com.
Walaa M S
WM
Ahmed
Department of Toxicology & Forensic Medicine, Faculty of Veterinary Medicine, Cairo University, Egypt.
A A
AA
Khalaf
Department of Toxicology & Forensic Medicine, Faculty of Veterinary Medicine, Beni-Suef University, Egypt.
Walaa A
WA
Moselhy
Department of Biochemistry, Faculty of Veterinary Medicine, Beni-Suef University, Egypt.
Ghada M
GM
Safwat
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000633:toxicity*; D001219:Aspartate Aminotransferases / Q000097:blood; D001379:Azathioprine / Q000633:toxicity*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D005227:Fatty Acids / Q000494:pharmacology / Q000627:therapeutic use*; D005978:Glutathione / Q000378:metabolism; D007970:Leukopenia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000099219:Royal Jelly
D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D000964:Antimetabolites, Antineoplastic; D001219:Aspartate Aminotransferases; D001379:Azathioprine; D005227:Fatty Acids; D005978:Glutathione; D020011:Protective Agents; D000099219:Royal Jelly
Azathioprine; Hepatotoxicity; Oxidative stress; Royal jelly